As popular as the peptide GLP‑1 boom has been worldwide, completely revolutionizing weight loss for millions, a common criticism is that this kind of treatment remains reserved for the upper class. Under that notion, Brazil is wrestling with whether its public healthcare system (SUS) should provide these drugs free of charge, sparking one of the most significant health policy debates of the year.
Just this year, the National Committee for Health Technology Incorporation (CONITEC) has officially recommended against adding GLP‑1 derivatives such as liraglutide and semaglutide to the SUS catalog for obesity treatment. Even with discounts, the annual cost of supplying these injections to Brazil’s vast population living with severe obesity would exceed R$ 8 billion, a figure the government argues is unsustainable.
Despite federal resistance, local authorities are testing ways to expand access. In early 2026, Rio de Janeiro became the first major city to directly purchase and distribute Ozempic through SUS, enrolling several hundred severely obese patients.
The Ministry of Health also launched the REAL‑BARI study in Porto Alegre, providing semaglutide to 250 patients awaiting bariatric surgery to evaluate whether the drug reduces hospitalization costs. Meanwhile, Goiás state has initiated a protocol to provide semaglutide to young people suffering from high‑risk obesity.
Domestic Production and Legal Pressure
Brazil is pursuing long‑term solutions to bypass high import costs. The Ministry of Health has partnered with Fiocruz and local pharmaceutical companies to manufacture generic versions of liraglutide and semaglutide, following semaglutide’s patent expiration in March 2026. At the same time, thousands of Brazilians are suing the government to gain access. Courts frequently order SUS to provide Ozempic for free to patients who can prove severe diabetes or obesity and lack the means to pay privately.
GLP‑1 drugs are peptide‑based therapies, and Brazil’s struggle to integrate them into public healthcare highlights the global challenge of balancing innovation with affordability. The country’s pilot projects, generics strategy, and judicial interventions could serve as a model for other nations facing similar cost barriers. For peptide researchers and companies, Brazil represents both a massive potential market and a test case for how public systems adapt to breakthrough metabolic treatments.
Related Coverage: For more on how GLP‑1 adoption is reshaping obesity trends, see our coverage of U.S. Obesity Rate Decline.
2 Responses